Great Lakes NeuroTechnologies Introduces KinesiaU™ For Objective Motor Assessment Using A Smartwatch

02 May 2019: Independence, OH – Great Lakes NeuroTechnologies (GLNT) announced today that it will be introducing the KinesiaU™ motor assessment system [ ] at the American Academy of Neurology Annual Meeting, which is being held in Philadelphia, PA, May 4 to May 10, 2019. KinesiaU is a validated, low-cost prescription consumer app for individuals to measure their Parkinson’s disease symptoms using an Android smartphone and smartwatch. The system tracks tremor, slowness, and dyskinesia as well as therapies and activities in user-friendly reports. These can help patients and clinicians make better care decisions and identify therapies and activities to improve their symptoms.

To use the device, the user performs two simple 7-second tasks throughout the day while wearing an Android smartwatch they may already own. Reports show symptoms as tested within the day and across days, weeks, months, and years in response to therapy and activities. A demo version of the KinesiaU app is freely available in the Google Play store; however, a patient must have a prescription to unlock the full version of the app that includes data reports.

The KinesiaU system builds upon Great Lakes NeuroTechnologies’ 15 years of development and validation of its patented Kinesia™ technology, which has been adopted as the gold-standard for objective sensor measurement for movement disorders by many of the world’s leading pharmaceutical and medical device companies. According to Great Lakes NeuroTechnologies President and COO, Dustin Heldman, Ph.D., “We are very excited to introduce the KinesiaU system, which will enable patients and doctors to track symptoms in real-time in response to therapy and activities using inexpensive consumer wearables. And with consumer wearables becoming commonplace, we are able to price the KinesiaU system an order of magnitude cheaper than our existing Kinesia systems that were designed for clinical trials.” Heldman adds that newly announced billing codes for remote monitoring of physiological data may provide coverage for the devices and for clinician time in reviewing reports and discussing treatment options with their patients. Parkinson’s patients who are interested should talk to their doctor about getting a prescription and the advantages of tracking their progress on a daily basis to provide improved therapy.

About Great Lakes NeuroTechnologies is committed to pioneering innovative biomed technologies to serve research, education, and medical communities, improving access to medical technology for diverse populations, and positively impacting quality of life for people around the world. Kinesia is a trademark of Great Lakes NeuroTechnologies Inc. of Independence, OH.

Media Contacts

Autumn Cox, 216-361-5410 –